Mindmed discovers, develops, and deploys psychedelic inspired medicines to improve health, promote wellness and alleviate suffering.
Bruce Linton said he will be a director at Mind Medicine, a Toronto-based company that is seeking to establish safe psychedelic-assisted treatments for mental illness, such as medicinal psilocybin and medicinal MDMA.
Mindmed is assembling a compelling pipeline of psychedelic inspired medicines for FDA clinical trials. We plan to deploy two types of drugs in the future:
A dose of generic psychedelics which causes a “trip”
Direct supervision by therapist & doctor
In-clinic treatment only
Derived from psychedelics, zero to negligible hallucination effect
Pharmacy pickup, take-home
Mindmed is establishing a proprietary R&D division focused on psychedelic inspired medicines.
Mindmed will also grow it's pipeline of psychedelic inspired medicines through acquisitions, Joint-Ventures and collaborative development agreements.
At present, 11 million americans are misusing opioids. Mindmed's immediate priority is to address the opioid crisis by developing an apparently non-hallucinogenic congener of the psychedelic ibogaine.
18-MC is a transformational treatment that targets the cause of addiction in the brain. 18-MC previously received $6.8m from the National Institute on Drug Abuse (NIDA), and is currently being prepared for a Phase II FDA clinical trial.